Inventor · disambiguated record
Timothy David Jones
Also filed as: JONES TIMOTHY · JONES TIMOTHY D · JONES TIMOTHY DAVID
40 granted patents·17 pending applications·818 citations·filing 2004–2023
97Inventor score
Files withCELLDEX THERAPEUTICS INC6JONES TIMOTHY DAVID6DANA FARBER CANCER INST INC4INTREXON CORP4SYNTIMMUNE INC4
Top patents by PatentIndex Score
57 records- 0198US9677055B2Modified forms of Pseudomonas exotoxin AINTREXON CORP·Filed 2016·Granted Jun 13, 2017·23 cites·23 claims
- 0298US9102727B2Human anti-PD-1 antibodies and uses thereforDANA FARBER CANCER INST INC·Filed 2013·Granted Aug 11, 2015·181 cites·21 claims
- 0397US8552154B2Anti-PD-L1 antibodies and uses thereforFREEMAN GORDON J·Filed 2009·Granted Oct 8, 2013·460 cites·12 claims
- 0496US10011656B2Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses thereforDANA FARBER CANCER INST INC·Filed 2015·Granted Jul 3, 2018·24 cites·11 claims
- 0595US10781267B2Methods of treating by administering anti-kit antibodiesCELLDEX THERAPEUTICS INC·Filed 2018·Granted Sep 22, 2020·7 cites·22 claims
- 0693US8932586B2Modified forms of Pseudomonas exotoxin AJONES TIMOTHY DAVID·Filed 2012·Granted Jan 13, 2015·11 cites·15 claims
- 0792US10184007B2Methods of treating a kit-associated cancer by administering anti-kit antibodiesCELLDEX THERAPEUTICS INC·Filed 2017·Granted Jan 22, 2019·9 cites·20 claims
- 0892US9605081B2Polynucleotides encoding anti-kit antibodiesKOLLTAN PHARMACEUTICALS INC·Filed 2016·Granted Mar 28, 2017·13 cites·8 claims
- 0990US10370448B2Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses thereforDANA FARBER CANCER INST INC·Filed 2018·Granted Aug 6, 2019·5 cites·18 claims
- 1090US9714290B2Humanised anti CTLA-4 antibodiesJONES TIMOTHY DAVID·Filed 2012·Granted Jul 25, 2017·18 cites·19 claims
- 1190US9447387B2Modified forms of pseudomonas exotoxin AINTREXON CORP·Filed 2015·Granted Sep 20, 2016·3 cites·22 claims
- 1290US9334332B2Anti-kit antibodiesKOLLTAN PHARMACEUTICALS INC·Filed 2013·Granted May 10, 2016·14 cites·58 claims
- 1388US11866509B2Humanized antibodies against CEACAM1FAMEWAVE LTD·Filed 2020·Granted Jan 9, 2024·2 cites·18 claims
- 1487US9371517B2Modified forms of Pseudomonas exotoxin AINTREXON CORP·Filed 2014·Granted Jun 21, 2016·3 cites·23 claims
- 1587US9321841B2Humanised anti-CD52 antibodiesJONES TIMOTHY DAVID·Filed 2012·Granted Apr 26, 2016·11 cites·21 claims
- 1687US2024150493A1Anti-kit antibodies and uses thereofCELLDEX THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1786US11891452B2Anti-kit antibodies and uses thereofCELLDEX THERAPEUTICS INC·Filed 2020·Granted Feb 6, 2024·1 cites·20 claims
- 1880US9988444B2Polypeptides comprising a modified bacteriophage g3p amino acid sequence with reduced immunogenicityPROCLARA BIOSCIENCES INC·Filed 2014·Granted Jun 5, 2018·4 cites·14 claims
- 1979US10626175B2Humanized affinity matured anti-FcRn antibodiesSYNTIMMUNE INC·Filed 2017·Granted Apr 21, 2020·2 cites·2 claims
- 2078US10550196B2Humanized antibodies against CEACAM1CCAM BIOTHERAPEUTICS LTD·Filed 2015·Granted Feb 4, 2020·3 cites·16 claims
- 2178US7879338B2Vectors and methods for immunization against norovirus using transgenic plantsTHOMPSON BOYCE PLANT RES·Filed 2004·Granted Feb 1, 2011·7 cites·29 claims
- 2277US11485792B2Antibodies, uses thereof and conjugates thereofPOLYTHERICS LTD·Filed 2017·Granted Nov 1, 2022·1 cites·31 claims
- 2376US10822417B2Humanized affinity matured anti-FcRn antibodiesSYNTIMMUNE INC·Filed 2017·Granted Nov 3, 2020·2 cites·9 claims
- 2476US9957317B2Humanized anti-tau antibodiesC2N DIAGNOSTICS LLC·Filed 2016·Granted May 1, 2018·2 cites·12 claims
- 2576US9073996B2Monoclonal antibodies for enhancing or inhibiting insulin-like growth factor 1 (IGF-1)UNIV NORTH CAROLINA·Filed 2013·Granted Jul 7, 2015·2 cites·5 claims
- 2673US11261251B2Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses thereforDANA FARBER CANCER INST INC·Filed 2019·Granted Mar 1, 2022·0 cites·19 claims
- 2773US10000567B2Humanized antibodies to cluster of differentiation 3 (CD3)THERAPIX BIOSCIENCES LTD·Filed 2013·Granted Jun 19, 2018·3 cites·19 claims
- 2871US9932402B2Humanized antibodies to iNKTNKT THERAPEUTICS INC·Filed 2012·Granted Apr 3, 2018·3 cites·7 claims
- 2971US9879076B2Methods and compositions with immune therapy for treatment of dementiaUNIV RAMOT·Filed 2014·Granted Jan 30, 2018·3 cites·29 claims
- 3071US9603911B2Ribotoxin molecules derived from sarcin and other related fungal ribotoxinsRES CORP TECH INC·Filed 2014·Granted Mar 28, 2017·1 cites·28 claims
- 3168US2017275600A1Modified forms of pseudomonas exotoxin aINTREXON CORP·Filed 2017·Application pending·0 cites
- 3267US11712477B2Compositions and methods for immunotherapyNEXIMMUNE INC·Filed 2020·Granted Aug 1, 2023·0 cites·14 claims
- 3362US11884734B2Anti-MET antibodies and methods of use thereofCELLDEX THERAPEUTICS INC·Filed 2020·Granted Jan 30, 2024·0 cites·16 claims
- 3462US2024092934A1Assessment of ceacam1 expression on tumor infiltrating lymphocytesFAMEWAVE LTD·Filed 2023·Application pending·0 cites
- 3560US2015031550A1Human antibodies and proteinsJONES TIMOTHY DAVID·Filed 2014·Application pending·0 cites
- 3660US2015031860A1Human antibodies and proteinsJONES TIMOTHY DAVID·Filed 2014·Application pending·0 cites
- 3759US2020207854A1HUMANIZED AFFINITY MATURED ANTI-FcRn ANTIBODIESSYNTIMMUNE INC·Filed 2020·Application pending·0 cites
- 3859US2020181262A1HUMANIZED AFFINITY MATURED ANTI-FcRn ANTIBODIESSYNTIMMUNE INC·Filed 2020·Application pending·0 cites
- 3958US11723951B2Polypeptides comprising a modified bacteriophage G3P amino acid sequence lacking a glycosylation signalAMYL THERAPEUTICS SRL·Filed 2020·Granted Aug 15, 2023·0 cites·21 claims
- 4057US11427647B2Polynucleotides encoding humanized antibodies against CEACAM1FAMEWAVE LTD·Filed 2019·Granted Aug 30, 2022·0 cites·19 claims
- 4157US10722551B2Polypeptides comprising a modified bacteriophage G3P amino acid sequence lacking a glycosylation signalPROCLARA BIOSCIENCES INC·Filed 2015·Granted Jul 28, 2020·0 cites·11 claims
- 4257US2016129133A1Compositions and methods for immunotherapyNEXIMMUNE·Filed 2014·Application pending·0 cites
- 4357US2008206239A1Human Antibodies And ProteinsANTITOPE LTD·Filed 2006·Application pending·0 cites
- 4455US8975377B2Cancer treatment using humanized antibodies that bind to EphB4GILL PARKASH·Filed 2008·Granted Mar 10, 2015·0 cites·8 claims
- 4555US2018214564A1Compositions and methods for immunotherapyNEXLMMUNE INC·Filed 2018·Application pending·0 cites
- 4655US2017210820A1Human antibodies and proteinsJONES TIMOTHY DAVID·Filed 2017·Application pending·0 cites
- 4753US9587024B2Monoclonal antibodies for enhancing or inhibiting insulin-like growth factor 1 (IGF-1)UNIV NORTH CAROLINA CHAPEL HILL·Filed 2015·Granted Mar 7, 2017·0 cites·35 claims
- 4852US2018016340A1Monoclonal Antibodies for Enhancing or Inhibiting Insulin-Like Growth Factor 1 (IGF-1)UNIV NORTH CAROLINA CHAPEL HILL·Filed 2017·Application pending·0 cites
- 4950US10035860B2Anti-alpha V beta 6 antibodies and uses thereofBIOGEN MA INC·Filed 2014·Granted Jul 31, 2018·0 cites·21 claims
- 5050US2018251534A1Polypeptides comprising a modified bacteriophage g3p amino acid sequence with reduced immunogenicityPROCLARA BIOSCIENCES INC·Filed 2018·Application pending·0 cites
Showing the top 50 of 57 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →